Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Call Transcript

Sheldon Koenig: Great. Thank you so much. And again, thank you for everyone for joining today for our Q3 2023 earnings. As you can see, I mean we’re very excited. We have a great story. We had a strong quarter. We really built upon our post-ACC momentum for NEXLIZET and NEXLETOL these are life-saving medications. We’re looking very forward to the PDUFA date or approval date of March 31. Again, as we mentioned, our litigation remains on track. We hope for a near term solution. However, again, if not the April 15 trial date. We will continue there. It’s important to remember NEXLETOL and NEXLIZET are novel therapies with differentiated first-in-class mechanism of action. And again, we’re a small company, but we’re doing big pharma things and we continue to deliver on all of our commitments. So again, thank you everyone. Have a great day. Maybe see some of you at American Heart and we’ll talk to you soon and take care.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.